病毒学报

参考文献

[1]Barrangou R,Fremaux C,Deveau H,Richards M,Boyaval P,Moineau S,Romero D,Horvath P.CRISPR provides acquired resistance against viruses in prokaryotes[J].Science,2007,315(5819):1709-1712.

[2]Yosef I,Goren M G,Qimron U.Proteins and DNA elements essential for the CRISPR adaptation process in Escherichia coli[J].Nucleic Acids Res,2012,40(12):5569-5576.

[3]Goldberg G W,Marraffini L A.Resistance and tolerance to foreign elements by prokaryotic immune systems-curating the genome[J].Nat Rev Immunol,2015,15(11):717-724.

[4]Marraffini L A.CRISPR/Cas immunity in prokaryotes[J].Nature,2015,526(7571):55-61.

[5]Mohanraju P,Makarova K S,Zetsche B,Diverse evolutionary roots and mechanistic variations of theCRISPR/Cas systems[J].Science,2016,353(6299):aad5147.

[6]Barrangou R,Horvath P.A decade of discovery:CRISPR functions and applications[J].Nat Microbiol,2017,2:17092.

[7]Jinek M,Chylinski K,Fonfara I,Hauer M,Doudna J,Charpentier E.A programmable dual-RNA-Guided DNA endonuclease in adaptive bacterial immunity[J].Science,2012,337(6096):816-821.

[8]Cong L,Ran F A,Cox D,Lin S,Barretto R,Habib N,Hsu P,Wu X,Jiang W,Marraffini L,Zhang F.Multiplex genome engineering using CRISPR/Cas systems[J].Science,2013,339(6121):819-823.

[9]Mali P,Yang L,Esvelt K M,Aach John,Guell Marc,DiCarlo J,Norville J,Church G.RNA-guided human genome engineering via Cas9[J].Science,2013,339(6121):823-826.

[10]Sternberg S H,Doudna J A.Expanding the biologist′s toolkit with CRISPR/Cas9[J].Mol Cell,2015,58(4):568-574.

[11]Jubair L,Mcmillan N a J.The Therapeutic Potential of CRISPR/Cas9 Systems in Oncogene-Addicted Cancer Types:Virally Driven Cancers as a Model System[J].Mol Ther-Nucleic Acids,2017,8:56-63.

[12]Trepo C,Chan H L Y,Lok A.Hepatitis B virus infection[J].Lancet,2014,384(9959):2053-2063.

[13]刘求明,尧晨光,郭晓红,胡康洪.抗乙肝病毒药物研究新进展[J].病毒学报,2016,32(5)650-658.

[14]Arzumanyan A,Reis H M G P V,Feitelson M A.Pathogenic mechanisms in HBV-and HCV-associated hepatocellular carcinoma[J].Nat Rev Cancer,2013,13(2):123-135.

[15]Lin S R,Yang H C,Kuo Y T,Liu C-J,Yang T Y,Sung K C,Lin Y Y,Wang H Y,Wang C C,Shen Y C,Wu F Y,Kao J H,Chen D S,Chen P J.The CRISPR/Cas9system facilitates clearance of the intrahepatic HBV templates in vivo[J/OL].Mol Ther-Nucleic Acids,2014,19;3:e186.

[16]Ramanan V,Shlomai A,Cox D B T,Schwartz R E,Michailidis E,Bhatta A,Scott D A,Zhang F,Rice C M,Bhatia S N.CRISPR/Cas9cleavage of viral DNA efficiently suppresses hepatitis B virus[J].Sci Rep,2015,Jun 2;5:10833.

[17]Seeger C,Sohn J A.Complete Spectrum of CRISPR/Cas9-induced Mutations on HBV cccDNA[J].Mol Ther,2016,24(7):1258-1266.

[18]Zhen S,Hua L,Liu Y H,Gao L C,Fu J,Wan D Y,Dong L H,Song H F,Gao X.Harnessing the clustered regularly interspaced short palindromic repeat(CRISPR)/CRISPR-associated Cas9system to disrupt the hepatitis B virus[J].Gene Ther,2015,22(5):404-412.

[19]Horst D,Ressing M E,Wiertz E J H J.Exploiting human herpesvirus immune evasion for therapeutic gain:potential and pitfalls[J].Immunol Cell Biol,2011,89(3):359-366.

[20]Menendez C M,Carr D J J.Defining nervous system susceptibility during acute and latent herpes simplex virus-1 infection[J].J Neuroimmunol,2017,308:43-49.

[21]Van Diemen F R,Kruse E M,Hooykaas M J G,Bruggeling C E,Schurch A C,van Ham P M,Imhof S M,Nijhuis M,Wiertz E J H J,Lebbink R J.CRISPR/Cas9-mediated genome editing of herpesviruses limits productive and latent infections[J/OL].PLoS Pathog,2016,Jun 30;12(6):e1005701.

[22]Wang J,Quake S R.RNA-guided endonuclease provides a therapeutic strategy to cure latent herpesviridae infection[J].Proc Natl Acad Sci U S A,2014,111(36):13157-13162.

[23]Zur Hausen H.Papillomaviruses and cancer:From basic studies to clinical application[J].Nat Rev Cancer,2002,2(5):342-350.

[24]Zhen S,Hua L,Takahashi Y,Narita S,Liu Y H,Li Y.In vitro and in vivo growth suppression of human papillomavirus 16-positive cervical cancer cells by CRISPR/Cas9[J].Biochem Biophys Res Commun,2014,450(4):1422-1426.

[25]Hu Z,Yu L,Zhu D,Ding W,Wang X,Zhang C,Wang L,Jiang X,Shen H,He D,Li K,Xi L,Ma D,Wang H.Disruption of HPV16-E7 by CRISPR/Cas aystem induces apoptosis and growth inhibition in HPV16positive human cervical cancer cells[J].Biomed Res Int,2014:612823.

[26]Liu Y-C,Cai Z-M,Zhang X-J.ReprogrammedCRISPR/Cas9targeting the conserved regions of HPV6/11E7genes inhibits proliferation and induces apoptosis in E7-transformed keratinocytes[J].Asian J Androl,2016,18(3):475-479.

[27]Sampson T R,Saroj S D,Llewellyn A C,Tzeng Y L,Weiss D S.A CRISPR/Cas system mediates bacterial innate immune evasion and virulence[J].Nature,2013,497(7448):254-257.

[28]Abudayyeh O O,Gootenberg J S,Konermann S,Joung J,Slaymaker I M,Cox D B T,Shmakov S,Makarova K S,Semenova E,Minakhin L,Severinov K,Regev A,Lander E S,Koonin E V,Zhang F.C2c2is a single-component programmable RNA-guided RNA-targeting CRISPR effector[J].Science,2016,353(6299):aaf5573.

[29]Price A A,Sampson T R,Ratner H K,Grakoui A,Weiss D S.Cas9-mediated targeting of viral RNA in eukaryotic cells[J].Proc Natl Acad Sci U S A,2015,112(19):6164-6169.

[30]Barre-Sinoussi F,Ross A L,Delfraissy J-F.Past,present and future:30years of HIV research[J].Nat Rev Microbiol,2013,11(12):877-883.

[31]王海鹏,陈承聪,王芳香,张萱萱,刘叔文,李琳.HIV潜伏感染激活剂的研究进展[J].病毒学报,2017,33(2):293-302.

[32]Ebina H,Misawa N,Kanemura Y,Koyanagi Y.Harnessing the CRISPR/Cas9 system to disrupt latent HIV-1provirus[J].Sci Rep,2013,3:2510.

[33]Kaminski R,Bella R,Yin C,Otte J,Ferrante P,Gendelman H E,Li H,Booze R,Gordon J,Hu W,Khalili K.Excision of HIV-1DNA by gene editing:aproofof-concept in vivo study[J].Gene Ther,2016,23(8-9):690-695.

[34]Allers K,Huetter G,Hofmann J,Loddenkemper C,Rieger K,Thiel E,Schneider T.Evidence for the cure of HIV infection by CCR5Delta 32/Delta 32stem cell transplantation[J].Blood,2011,117(10):2791-2799.

[35]Ye L,Wang J,Beyer A I,Teque F,Cradick T J,Qi Z,Chang J C,Bao G,Muench M O,Yu J,Levy J A,Kan Y W.Seamless modification of wild-type induced pluripotent stem cells to the natural CCR5 Delta 32mutation confers resistance to HIV infection[J].Proc Natl Acad Sci U S A,2014,111(26):9591-9596.

[36]Fine E J,Appleton C M,White D E,Deshmukh H,Kemp M L,Bao G.Trans-spliced Cas9allows cleavage of HBB and CCR5genes in human cells using compact expression cassettes[J].Sci Rep,2015,5:10777.

[37]Li C,Guan X,Du T,Jin Wei,Wu B,Liu Y,Wang P,Hu B,Griffin G E,Shattock R J,Hu Q.Inhibition of HIV-1infection of primary CD4(+)T-cells by gene editing of CCR5using adenovirus-delivered CRISPR/Cas9[J].J Gen Virol,2015,96:2381-2393.

[38]Peled A,Petit I,Kollet O,Magid M,Ponomaryov T,Byk T,Nagler A,Ben-Hur H,Many A,Shultz L,Lider O,Alon R,Zipori D,Lapidot T.Dependence of human stem cell engraftment and repopulation of NOD/SCID mice on CXCR4[J].Science,1999,283(5403):845-848.

[39]Hou P,Chen S,Wang S,Yu X,Chen Y,Jiang M,Zhuang K,Ho W,Hou W,Huang J,Guo D.Genome editing of CXCR4by CRISPR/cas9confers cells resistant to HIV-1infection[J].Sci Rep,2015,5:15577.

[40]Bogerd H P,Kornepati A V R,Marshall J B,Kennedy E M,Cullen B R.Specific induction of endogenous viral restriction factors using CRISPR/Cas-derived transcriptional activators[J/OL].Proc Natl Acad Sci U S A,2015,112(52):E7249-E7256.

[41]Gootenberg J S,Abudayyeh O O,Lee J W,Essletzbichler P,Dy A J,Joung J,Verdine V,Donghia N,Daringer N M,Freije C A,Myhrvold C,Bhattacharyya R P,Livny J,Regev A,Koonin E V,Hung D T,Sabeti P C,Collins J J,Zhang F.Nucleic acid detection with CRISPR/Cas13a/C2c2[J].Science,2017,356(6336):438-442.

[42]Gori J L,Hsu P D,Maeder M L,Shen S,Welstead G G,Bumcrot D.Delivery and specificity of CRISPR/Cas9genome editing technologies for human gene therapy[J].Hum Gene Ther,2015,26(7):443-451.

[43]Duan D.Systemic delivery of adeno-associated viral vectors[J].Curr Opin Virol,2016,21:16-25.

[44]Yin H,Song C-Q,Dorkin J R,Zhu L J,Li Y,Wu,Q,Park A,Yang J,Suresh S,Bizhanova A,Gupta A,Bolukbasi,M F,Walsh,S,Bogorad R L,Gao G,Weng Z,Dong Y,Koteliansky V,Wolfe S,Langer R,Xue W,Anderson D G.Therapeutic genome editing by combined viral and non-viral delivery of CRISPR system components in vivo[J].Nat Biotechnol,2016,34(3):328-333.

[45]Yang Y,Wang L,Bell P,McMenamin D,He Z,White J,Yu H,Xu C,Morizono H,Musunuru K,Batshaw M L,Wilson J M.A dual AAV system enables the Cas9-mediated correction of a metabolic liver disease in newborn mice[J].Nat Biotechnol,2016,Mar;34(3):334-338.

[46]Chew W L,Tabebordbar M,Cheng J K W,Mali P,Wu E Y,Ng A H M,Zhu K,Wagers A J,Church G M.A multifunctional AAV-CRISPR/Cas9and its host response[J].Nat Methods,2016,Oct;13(10):868-874.

[47]Hsu P D,Scott D A,Weinstein J A,Ran F A,Konermann S,Agarwala V,Li Y,Fine E J,Wu X,Shalem O,Cradick T J,Marraffini L A,Bao G,Zhang F.DNA targeting specificity of RNA-guided Cas9nucleases[J].Nat Biotechnol,2013,31(9):827-832.

[48]Kleinstiver B P,Prew M S,Tsai S Q,Topkar V V,Nguyen N T,Zheng Z,Gonzales A P W,Li Z,Peterson R T,Yeh J J,Aryee M J,Joung J K.Engineered CRISPR/Cas9nucleases with altered PAM specificities[J].Nature,2015,523(7561):481-485.

[49]袁伟曦,喻云梅,胡春财,赵祖国.CRISPR/Cas9技术存在的问题及其改进措施的研究进展[J].生物技术通报,2017,33(4):70-77.